Human papillomavirus-positive oral cavity and oropharyngeal cancer patients do not have better quality-of-life trajectories.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 22275190.
- Also identified by DOI 10.1177/0194599811434707 and PMC identifier 3535430.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine the role of human papillomavirus (HPV) status on quality of life (QOL) in patients with oral cavity and oropharyngeal squamous cell carcinoma (OSCC). Since OSCC that are associated with high-risk HPV have an improved response to treatment and survival, we hypothesized that patients with these tumors would have better QOL trajectories. Prospective cohort study. Tertiary care academic medical center and 2 affiliated hospitals. Head and neck-specific QOL was determined using the University of Washington Quality of Life scale version 4 in patients with newly diagnosed invasive OSSC (N = 228). Pretreatment QOL was higher in patients with high-risk HPV-associated tumors compared with patients with HPV-negative or low-risk HPV-associated tumors (P = .015). Patients with high-risk HPV-associated tumors had larger decreases in QOL from pretreatment to immediate posttreatment compared with patients with HPV-negative or low-risk HPV-associated tumors (P = .041). There was no association between HPV status and 1-year posttreatment QOL. Among OSCC patients, high-risk HPV-associated tumors were associated with higher pretreatment QOL and a larger decrease in QOL from pretreatment to immediate posttreatment, suggesting that treatment intensity in this unique population may adversely affect QOL.
Medical subject headings
- Mouth Neoplasms
- Oropharyngeal Neoplasms
- Papillomavirus Infections
- Quality of Life